Table 2.
Potentiating Effect of Physostigmine and Rivastigmine on AFDX-116 and R(+)-hyoscyamine -induced Analgesia in the Mouse Hot-plate Test.
| Licking Latency in Mice (s) | |||||
|---|---|---|---|---|---|
| TREATMENT | TREATMENT | Before | After Treatment | ||
| Treatment | 15 Min | 30 Min | 45 Min | ||
| SALINE | SALINE | 15.2 ± 1.1 | 14.7 ± 1.5 | 13.2 ± 2.0 | 14.6 ± 1.9 |
| SALINE | AFDX-116 | 16.1 ± 1.2 | 23.2 ± 2.1* | 20.7 ± 1.9* | 16.3 ± 1.5 |
| SALINE | R-(+)-HYOSCIAMINE | 13.9 ± 0.9 | 24.7 ± 1.9* | 22.6 ± 1.7* | 17.1 ± 1.8 |
| PHYSOSTIGMINE | SALINE | 14.8 ± 1.2 | 25.6 ± 2.6* | 21.7 ± 1.9* | 19.3 ± 2.0 |
| PHYSOSTIGMINE | AFDX-116 | 15.0 ± 1.1 | 36.5 ± 1.7* | 35.2 ± 1.6* | 24.0 ± 1.7* |
| PHYSOSTIGMINE | R-(+)-HYOSCIAMINE | 14.3 ± 1.5 | 39.1 ± 2.4* | 36.2 ± 2.3* | 26.7 ± 2.8* |
| RIVASTIGMINE | SALINE | 14.3 ± 1.1 | 26.2 ± 2.1* | 22.5 ± 1.2* | 17.5 ± 1.2 |
| RIVASTIGMINE | AFDX-116 | 13.2 ± 1.7 | 38.7 ± 2.8* | 35.5 ± 2.6* | 22.9 ± 1.8* |
| RIVASTIGMINE | R-(+)-HYOSCIAMINE | 14.5 ± 1.2 | 37.0 ± 3.2* | 34.6 ± 2.9* | 26.5 ± 1.6* |
AFDX-116 (0.1μg i.c.v.) and R-(+)-hyoscyamine (10μg i.c.v.) were administered 30 min after rivastigmine (0.75mg kg-1 s.c ) and physostigmine (0.075mg kg-1 s.c). There were at least 12 mice per group.
*
P < 0.01, versus control mice.
ˆ
P < 0.01 versus saline AFDX/R-(+)-hyosciamine [40].